Pregnancy‐driven cardiovascular maternal miR‐29 plasticity in obesity. Issue 6 (15th September 2016)

• Record Type: Journal Article
• Authors: Schlabritz‐Loutsevitch, N.; Apostolakis‐Kyrus, K.; Krutilina, R.; Hubbard, G.; Kocak, M.; Janjetovic, Z.; Sathanandam, S.; Slominski, A. T.; Mari, G.; Dick, E.
• Is Part Of: Journal of medical primatology. Volume 45:Issue 6(2016)
• Page Start: 297
• Page End: 303
• Publication Date: 2016-09-15
• Subjects: maternal obesity -- non‐human primate -- vascular remodeling; Primates -- Periodicals; Primates -- Diseases -- Periodicals; Medicine, Experimental -- Periodicals; 616.02738
• DOI: 10.1111/jmp.12236
• Languages: English
• ISSNs: 0047-2565

Abstract

Abstract: Background: Obesity in pregnancy (MO) is a risk factor for maternal and/or fetal cardiovascular system disorders. This study evaluated maternal CVS expression of microRNA‐29 family and its target molecules in MO to test the hypotheses: CVS miR‐29 concentrations are increased in pregnancy and decreased in MO. Methods: Non‐pregnant (n=4), pregnant obese (POb, n=4), and pregnant non‐obese (PnOb, n=4) baboons ( Papio spp.) were studied. Maternal left ventricle (LV), left atrium (LA), and aortic arch (AA) were collected at the end of gestation. Expression of MiR‐29 and elastin ( ELN ) mRNA were quantified. Results: LA miR‐29 (a, c) expression was highest in PnOb. In the LV, miR‐29b expression trended lower ( P =.059) for PnOb animals. ELN mRNA expression correlated positively with miR‐29b expression in AA ( r =.76, P =.03). Conclusion: Maternal obesity diminishes miR‐29 adaptation to pregnancy. Pharmacologic, tissue‐specific targeting of miRNA‐29 may represent a strategy for prevention and treatment of MO complications.